Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Why the Earnings Surprise Streak Could Continue for Baxter (BAX)
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What Makes Baxter (BAX) a New Buy Stock
by Zacks Equity Research
Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
Baxter Showcases PN Product Portfolio at ASPEN Conference
by Zacks Equity Research
The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.
Moving Average Crossover Alert: Baxter International
by Zacks Equity Research
Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Fresenius Medical's New Hemodialysis Software Gets FDA Nod
by Zacks Equity Research
Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.
Baxter (BAX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Moving Average Crossover Alert: Baxter International
by Zacks Equity Research
Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Baxter (BAX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
Top Analyst Reports for Home Depot, Oracle & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Oracle (ORCL) and Union Pacific (UNP).
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Baxter's Acute Therapies Profile Strong, Competition Rife
by Zacks Equity Research
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.
Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Baxter International (BAX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?
by Zacks Equity Research
Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.
Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.
Stock Market News For Jan 18, 2019
by Zacks Equity Research
Benchmarks ended in the green on Thursday, extending the streak of gains to three days on the trot.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.